Currently out of the existing stock ratings of Maury Raycroft, 145 are a BUY (86.83%), 22 are a HOLD (13.17%).

Maury Raycroft

Work Performance Price Targets & Ratings Chart

Analyst Maury Raycroft, currently employed at JEFFERIES, carries an average stock price target met ratio of 54.11% that have a potential upside of 38.96% achieved within 188 days.

Maury Raycroft’s has documented 327 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on TYRA, Tyra Biosciences at 02-Feb-2026.

Wall Street Analyst Maury Raycroft

Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS) at 9/18/2017. The price target of $102 was fulfilled within 2 days with a profit of $26 (34.21%) receiving and performance score of 171.05.

Average potential price target upside

AFMD Affimed NV ARWR Arrowhead Pharmaceuticals ATRA Atara Biotherapeutics AYLA Ayala Pharmaceuticals  BCRX BioCryst Pharmaceuticals CRBP Corbus Pharmaceuticals CRSP Crispr Therapeutics AG KALV Kalvista Pharmaceuticals MRTX Mirati Ther RETA Reata Pharmaceuticals SRRA Sierra Oncology ALLK Allakos ABEO Abeona Therapeutics ALNY Alnylam Pharmaceuticals EIGR Eiger Biopharmaceuticals NTLA Intellia Therapeutics BYSI BeyondSpring VALN Valneva SE ADR XENE Xenon Pharmaceuticals FMTX Forma Therapeutics Holdings KPTI Karyopharm Therapeutics RARE Ultragenyx SGMO Sangamo Therapeutics IMGO Imago Biosciences VERA Vera Therapeutics CNST Constellation Pharmaceuticals RTRX Travere Therapeutics SBPH Spring Bank Pharmaceuticals THRX Theseus Pharmaceuticals TYRA Tyra Biosciences RZLT Rezolute SPPI Spectrum Pharmaceuticals KZR Kezar Life Sciences AUPH Aurinia Pharmaceuticals CALT Calliditas Therapeutics CMPX Compass Therapeutics CUE Cue Biopharma DNTH Dianthus Therapeutics CELC Celcuity LLC CMRX Chimerix CNCE Concert Pharmaceuticals FSTX FStar Therapeutics MITO Stealth BioTherapeutics Corp OPK Opko Health ZLAB Zai Lab Ltd ORIC Oric Pharmaceuticals  BEAM Beam Therapeutics  CMP Compass Minerals International CMPI Checkmate Pharmaceuticals KOD Kodiak Sciences LOGC LogicBio Therapeutics PRME Prime Medicine, Common Stock SLDB Solid Biosciences LLC THR MGX Metagenomi, Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$10

1 years 7 months 12 days ago
(18-Dec-2024)

6/12 (50%)

$7.68 (331.03%)

78

Buy

$25

1 years 7 months 18 days ago
(12-Dec-2024)

4/5 (80%)

$18.65 (293.70%)

126

Buy

1 years 8 months 11 days ago
(19-Nov-2024)

5/5 (100%)

$2.27 (47.99%)

266

Hold

$4

$2.97 (288.35%)

$5

1 years 8 months 15 days ago
(15-Nov-2024)

2/3 (66.67%)

$0.52 (14.94%)

82

Buy

$25

$23.97 (2327.18%)

2 years 1 months 18 days ago
(12-Jun-2024)

1/2 (50%)

$18.14 (264.43%)

1324

Show more analysts

Please expand the browser size to see the chart

Which stock is Maury Raycroft is most bullish on?

Potential upside of $12.37 has been obtained for TYRA (TYRA BIOSCIENCES)

Which stock is Maury Raycroft is most reserved on?

Potential downside of -$22.87 has been obtained for DNTH (DIANTHUS THERAPEUTICS)

What Year was the first public recommendation made by Maury Raycroft?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?